#MarketAccessRiskAssessment #Pricing #Reimbursement #MarketAccess #MARArating
#Company #Drug
White House seeks 12% cut to HHS in 2027
Summary
The White House has proposed a 12% cut to the Department of Health and Human Services (HHS) in its 2027 budget request. This includes significant cuts to health agencies such as the National Institutes of Health (NIH), the Agency for Healthcare Research and Quality (AHRQ), and the creation of a new agency, the Administration for a Healthy America (AHA). These cuts are part of the administration’s efforts to constrain non-defense spending and reform the federal government.
Access impact
The proposed budget would result in a 12% decrease in funding for HHS, which could have significant implications for pricing and reimbursement in the healthcare industry. The cuts to agencies like the NIH and AHRQ could impact the availability of funding for research and development of new treatments and therapies. This could potentially limit the number of new drugs and treatments available to patients, and also impact the cost of these treatments.
Top-3 domain lens
Clinical Effectiveness
The proposed cuts to the NIH and AHRQ could impact the availability of funding for research into clinical effectiveness and safe healthcare delivery practices. This could result in a lack of evidence supporting the effectiveness of treatments and therapies, leading to uncertainty and potential difficulties in obtaining reimbursement for these treatments.
Budget Impact and Resources
The proposed budget also aims to consolidate and eliminate programs under various health agencies, which could impact the availability of resources and funding for healthcare programs. This could result in challenges for patients in accessing necessary healthcare resources and services, as well as potential budget constraints for healthcare providers and organizations.
Evidence Quality and Robustness
The proposed cuts to the NIH and AHRQ could also impact the quality and robustness of evidence supporting treatments and therapies. This could lead to uncertainty and potential inequities in access to certain treatments, as well as challenges in obtaining reimbursement for these treatments.
Hashtags
#MarketAccessRiskAssessment #Pricing #Reimbursement #MarketAccess #MARArating
#Company #Drug
CTA
Explore 350+ independent assessments: https://mararating.com/mara-ratings-list
Source
source: https://www.biopharmadive.com/news/white-house-hhs-2027-fiscal-year-budget-request-12-percent-cut/816671/